A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
NCT05533814
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
125
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
Perampanel
Sponsor
Eisai Korea Inc.